Fennec Pharmaceuticals (FENC) ex-director receives 2,778 common shares

Rhea-AI Filing Summary

FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov acquired 2,778 common shares on 2026-07-31 in a transaction coded as a grant or award. The shares represent stock released from restriction from an award granted on 5/16/2024, bringing his direct holdings to 141,633 common shares.

Insider Trade Summary

Net Buyer: 2,778 shares

Net Buy 1 txn

Insider Raykov Rosty

Role Insider

Type	Security	Shares	Price	Value
Grant/Award	Common shares F1	2,778	$0.00	$0.00

Holdings After Transaction: Common shares — 141,633 shares (Direct)

Footnotes (1)

1. F1. Represents shares released from restriction from shares awarded 5/16/2024.

Key Figures

Common shares acquired: 2,778 shares Reported price per share: $0.0000 Shares owned after transaction: 141,633 shares

3 metrics

Common shares acquired 2,778 shares Grant/award acquisition on 2026-07-31

Reported price per share $0.0000 For the 2,778 common shares acquired

Shares owned after transaction 141,633 shares Direct ownership by Rosty Raykov following 2026-07-31 award

Key Terms

Grant, award, or other acquisition, restricted shares, Common shares

3 terms

Grant, award, or other acquisition regulatory

"Transaction coded as A for a grant, award, or other acquisition."

restricted shares financial

"Represents shares released from restriction from shares awarded 5/16/2024."

Restricted shares are company stock that cannot be sold or transferred immediately because they are subject to legal or contractual limits, such as a required holding period or performance conditions. They matter to investors because these locked-up shares can affect a company’s available stock for trading, future dilution, and insider incentives—imagine a gift that can’t be cashed until certain conditions are met, which changes when and how much supply can suddenly enter the market.

Common shares financial

"Security title reported as Common shares acquired by the insider."

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/03/2026 - 04:05 PM Accepted by SEC EDGAR 08/03/2026 - 04:05 PM Learn about SEC filing dates

FAQ

What insider transaction did FENNEC PHARMACEUTICALS INC. (FENC) report for Rosty Raykov?

FENNEC PHARMACEUTICALS INC. reported that former director Rosty Raykov acquired 2,778 common shares on 2026-07-31. The shares came from the release of restrictions on stock originally awarded on 5/16/2024, increasing his direct holdings to 141,633 shares.

How many FENC shares does former director Rosty Raykov own after this Form 4 transaction?

After the reported transaction, former director Rosty Raykov directly owns 141,633 common shares of FENNEC PHARMACEUTICALS INC. This reflects the addition of 2,778 shares that became unrestricted from a prior stock award granted on 5/16/2024.

What was the nature of the 2,778-share transaction reported for FENC on 2026-07-31?

The 2,778-share transaction for FENNEC PHARMACEUTICALS INC. was a grant, award, or other acquisition coded "A". A footnote explains it represents shares released from restriction from an award granted on 5/16/2024, rather than an open-market purchase.

At what reported price were the 2,778 FENC shares acquired by Rosty Raykov?

The 2,778 common shares acquired by former director Rosty Raykov were reported at a per-share price of $0.0000. This reflects the accounting of the stock award vesting, as the shares came from restrictions lapsing on a previously granted award.

Does the FENC Form 4 indicate this insider transaction involved restricted shares becoming unrestricted?

Yes. A footnote states the 2,778 common shares represent shares released from restriction from shares awarded on 5/16/2024. This means the transaction reflects vesting or lapse of restrictions, not a new cash purchase in the market.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Raykov Rosty

(Last) (First) (Middle)

C/O FENNEC PHARMACEUTICALS, INC.

PO BOX 13628, 68 TW ALEXANDER DRIVE

(Street)

RESEARCH TRIANGLE PARK NORTH CAROLINA 27709

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
FENNEC PHARMACEUTICALS INC. [ FENC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
	Officer (give title below)	X	Other (specify below)
			Former Director

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common shares(1)	07/31/2026		A		2,778	A	$0	141,633	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares released from restriction from shares awarded 5/16/2024.

	/s/ Rosty Raykov	08/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)